Skip to main content
Premium Trial:

Request an Annual Quote

Dako Signs Another CDx Agreement with Amgen

NEW YORK (GenomeWeb) – Dako, an Agilent Technologies company, today announced it has signed an additional collaboration with Amgen to develop a companion diagnostic for an unspecified Amgen cancer drug candidate.

In an email to GenomeWeb, Agilent declined to provide additional details about the agreement.

The deal builds on agreements from 2012 between the two companies, under which Dako was developing several companion diagnostics for drugs from Amgen.

Dako also has inked similar companion diagnostic agreements with several pharma firms over the past few years including AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Genentech.